RWD71 Real-World Usage and Pattern of Biosimilar Monoclonal Antibodies of Trastuzumab, Rituximab and Bevacizumab in Oncology Practice in Japan

Abstract

Oncology biosimilars hold the promise of reducing costs in Japan. Although the adoption of oncology biosimilars have been modest due to physicians’ perceptions and lack of operational guidance that supports usage to biosimilars, Japan showed an increase in the uptake of biosimilars.